Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases
ID: NIH/NIAID 128 Type: BOTH
Overview

Topic

Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451733

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The solicitation, titled "Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases," aims to support the pre-clinical development of vaccine adjuvants for use in vaccines to prevent or treat human diseases caused by infectious pathogens or immune-mediated diseases.

Vaccine adjuvants are agents that stimulate and direct the immune system, enhancing or modulating immune responses to a target antigen. They can influence the quality, magnitude, tissue distribution, isotype and subclass, and duration of antibody responses elicited by a vaccine. Adjuvants also play a role in driving antigen-specific CD8 T cell responses, which are crucial for protection against certain pathogens. Adjuvants are particularly important in improving vaccine efficacy in at-risk populations such as neonates, young children, pregnant women, the immunocompromised, and the elderly, who have unique immune system characteristics and needs.

The solicitation emphasizes the need for new, improved, and widely accessible adjuvants to support vaccine development. Different pathogens or immune-mediated diseases require different immune responses for protection or treatment, necessitating the use of appropriate adjuvants for each vaccine. Adjuvants can also accommodate different routes of administration or antigens with varying formulation needs. Additionally, having additional options, including functional mimics of late-stage adjuvants or adjuvants in licensed vaccines, would offer more flexibility to vaccine developers.

The solicitation accepts Fast-Track proposals and Direct-to-phase II proposals. The anticipated number of awards is 1-3, and the budget specifics are as follows:

  • Phase I: $300,000/year for up to 2 years
  • Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years

The project duration and funding specifics are provided to guide potential applicants. The solicitation is closed, and more information can be found on the grants.gov website (solicitation_agency_url) and the SBIR topic link (sbir_topic_link).

Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Innovation Research (SBIR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and tools for monitoring cognitive function. The solicitation is open until September 8, 2025, with multiple application due dates throughout the year. More information can be found on the grants.gov and NIH websites.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Innovation Research (SBIR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and tools for monitoring cognitive function. The solicitation is open until September 8, 2025, with multiple application due dates throughout the year. More information can be found on the grants.gov website.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). The goal of this solicitation is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and educational training programs. The solicitation is open for applications until September 6, 2025, and the funding will be provided through the Small Business Technology Transfer (STTR) program. For more information and to submit a proposal, visit the grants.gov website or the National Institutes of Health's solicitation page.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and genetic analysis tools. The solicitation is open until September 6, 2025, and multiple application due dates are provided. For more information and to apply, visit the SBIR topic link [here](https://www.sbir.gov/node/2230637) and the solicitation agency URL [here](https://grants.nih.gov/grants/guide/PA-files/PAS-22-197.html).